Format

Send to

Choose Destination
Curr Med Chem. 2000 Jun;7(6):663-72.

Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor.

Author information

1
Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California, 94404, USA.

Abstract

Rational drug design utilizing available X-ray crystal structures of sialic acid analogues bound to the active site of influenza virus neuraminidase has led to the discovery of a series of potent carbocyclic influenza neuraminidase inhibitors. From this series, GS 4104 (oseltamivir, TAMIFLU ) has emerged as a promising antiviral for the treatment and prophylaxis of human influenza infection. This article will summarize the design, discovery, and development of oseltamivir as an oral therapeutic to treat influenza infection.

PMID:
10702632
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center